Pacific Biosciences of California, Inc.
PACB
position
long
William C. Martin
Thesis
We bought Pacific Biosciences at a low market cap, believing in its long-term potential in the genomic sequencing space, despite its current cash burn and competitive risks.
Did it work?
failed
confidence: high
The stock price has decreased by 100% since the pitch, indicating a total loss of value, which directly contradicts the long thesis. Despite the belief in its long-term potential, the significant cash burn and competitive risks have likely undermined the company's viability, leading to this drastic decline.
Raw excerpt
No raw excerpt stored.